Outcomes of Allogeneic Stem Cell Transplant (Allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in Patients Older Than 75 Years: A Single Center Analysis

被引：0
作者：
Nath, Rajneesh [1 ]
Cerny, Jan [2 ]
Ramanathan, Muthalagu [3 ]
Zhou, Zheng [2 ]
Yu, Neng [4 ]
Raffel, Glen D. [5 ]
Bednarik, Jayde [6 ]
机构：
[1] Banner MD Anderson Canc Ctr, Div Hematol Oncol, BMT & Acute Leukemia Program, Gilbert, AZ USA
[2] Univ Massachusetts, Med Sch, Dept Med, Div Hematol Oncol, Worcester, MA USA
[3] Univ Massachusetts Mem Ctr, Div Hematol, Dept Internal Med, Worcester, MA USA
[4] UMass Mem Med Ctr, HLA Lab, Worcester, MA USA
[5] Univ Massachusetts Med Sch, Div Hematol Oncol, Worcester, MA USA
[6] UMass Mem Med Ctr, Worcester, MA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5875.5875
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5875
引用
收藏
页数：5
相关论文
共 50 条
  • [41] CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
    William, Basem M.
    de Lima, Marcos
    Oran, Betul
    Champlin, Richard
    Papadopoulos, Esperanza B.
    Giralt, Sergio
    Scott, Bart L.
    Hetzer, Joel
    Wang, Xiwei
    Laille, Eric
    Skikne, Barry S.
    Craddock, Charles
    BLOOD, 2014, 124 (21)
  • [42] The role of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) in patients with acute myeloid leukemia (AML): A donor vs. no donor comparison.
    de la Vallade, H
    Mohty, M
    Faucher, C
    Vey, N
    Coso, D
    Stoppa, AM
    Gastaut, JA
    Ladaique, P
    Chabannon, C
    Blaise, D
    BLOOD, 2004, 104 (11) : 640A - 640A
  • [43] Impact of Conditioning Intensity on Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Patients with Acute Leukemia and Myelodysplastic Syndromes
    Shahzad, Moazzam
    Amin, Muhammad Kashif
    Rehman, Aqeeb Ur
    Mohsin, Aleenah
    Mcguirk, Matthew
    Chaudhary, Sibgha Gull
    Anwar, Iqra
    Abdelhakim, Haitham
    Singh, Anurag K.
    Hamadani, Mehdi
    Mcguirk, Joseph P.
    Mushtaq, Muhammad Umair
    BLOOD, 2024, 144 : 4860 - 4861
  • [44] Lack of impact of comorbidities on outcomes of allogeneic stem cell transplantation (ASCT) for refractory acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS)
    Wong, RS
    Shahjahan, M
    Alamo, J
    de Lima, M
    Khouri, I
    Gajewski, J
    Andersson, B
    Champlin, R
    Giralt, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 31 - 31
  • [45] Age Does Not Adversely Influence Outcomes among Patients Older than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Modi, Dipenkumar
    Deol, Abhinav
    Kim, Seongho
    Ayash, Lois
    Alavi, Asif
    Ventimiglia, Marie
    Bhutani, Divaya
    Ratanatharathorn, Voravit
    Uberti, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S282 - S283
  • [46] Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT
    Craddock, Charles
    Labopin, Myriam
    Houhou, Mohamed
    Robin, Marie
    Finke, Juergen
    Chevallier, Patrice
    Yakoub-Agha, Ibrahim
    Bourhis, Jean-Henri
    Sengelov, Henrik
    Blaise, Didier
    Dreger, Peter
    Hallek, Michael
    Nagler, Arnon
    Kroger, N.
    Mohty, Mohamad
    BLOOD, 2014, 124 (21)
  • [47] Prognostic factors for allogeneic stem cell transplantation (ASCT) for refractory acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS).
    Wong, R
    Shahjahan, M
    De Lima, M
    Anagnostopoulos, A
    Estey, E
    Champlin, R
    Andersson, B
    Khouri, I
    Giralt, S
    BLOOD, 2002, 100 (11) : 853A - 853A
  • [48] Allogeneic stem cell transplantation (Allo-SCT) for Acute Lymphoblastic Leukemia (ALL) in adult patients - are we doing better?
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S103 - S104
  • [49] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND SECONDARY ACUTE MYELOID LEUKEMIA - THE RETROSPECTIVE ANALYSIS
    Vondrakova, J.
    Belohlavkova, P.
    Zapletalova, J.
    Raida, L.
    Zak, P.
    Jebavy, L.
    Voglova, J.
    Zavrelova, A.
    Pikalova, Z.
    Skoumalova, I
    Jarosova, M.
    Faber, E.
    Maly, J.
    Indrak, K.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S321 - S321
  • [50] Decitabine As Induction Therapy For Median-To-High-Risk Myelodysplastic Syndromes(MDS) and Acute Myeloid Leukemia(AML) Before Allogeneic Stem Cell Transplantation
    Zhou, Lin
    Wu Depei
    Fu, Chengcheng
    Sun, Aining
    Qiu, Huiying
    Jin, Zhengming
    Tang, XiaoWen
    Han, Yue
    Ma, Xiao
    He, Guangsheng
    BLOOD, 2013, 122 (21)
12345